THE IMPORTANCE of making the distinction between acute lymphoblastic and acute myelogenous leukaemia lies in their different response to cytotoxic drugs, and in consequence the different median survival. The most successful therapy for the induction of remission in acute myelogenous leukaemia is with regimens that employ cytosine arabinoside, either in combination with daunorubicin (Crowther et al., 1970 (Crowther et al., , 1973 or 6-mercaptopurine (6MP) (Bailey et al., 1971) , or 6-thioguanine (Clarkson, 1972) . Only a small proportion of patients with acute lymphoblastic leukaemia fail to respond to prednisone and vincristine therapy, at least in children (Simone et al., 1972) . Some workers have found it impossible to distinguish between acute lymphoblastic and acute myelogenous leukaemias in adults, and have adopted protocols which include drugs that are effective in the treatment of both diseases (Whitecar et al., 1972) . Notwithstanding this, Mathe and his colleagues (Mathe, Bernard and Meaume, 1959; Mathe et al., 1971) have further subdivided acute myelogenous and acute lymphoblastic leukaemia and related the subsequent cytological sub-groups to remission length and survival.
Both these groups have found cytochemistry unhelpful whereas other workers have put great store in the results of cytochemical tests (Hayhoe and Flemens, 1969;  Schmalzl and Braunsteiner, 1971 Induction of remission in patients with ALL was w-ith prednisone 40 mg/M2 daily for 3 weeks, orally, and vincristine 1-5 mg/M2 weekly for 3 doses, intravenously. In 4 cases complete remission was not obtained on these agents alone and other drugs -were added-Adriamycin in one case, cytosine arabinoside and daunorubicin in 2 cases, and asparaginase, 6MP and daunorubicin in the fourth case. Remission in some patients with ALL treated initially at outside hospitals was induced with a mixture of different agents including prednisolone, vincristine, 6MP, methotrexate and asparaginase. The first 28 patients with AMIL w-ere treated initially with cytosine arabinoside 0 75 mg/kg intravenously 8-hourly for 9 doses, followed by daunorubicin 1-5 ing/kg intravenously 72 h after the last dose of cytosine arabinoside. The courses wNere repeated with 5-day gaps until remission ensued or until 6 courses had been completed without success. In the latter event treatment with 6-thioguanine 2-5 mg/kg orally daily and cyclophosphamide 200 mg/M2 orally weekly was substituted. The last 18 patients with AML have been treated with cytosine arabinoside 10 mg/kg in 1 litre of normal saline by intravenous infusion over 24 h. Daunorubicin 15 mg/kg was given intravenously at the end of the infusion. Patients who failed to remit on this regimen were given cytosine in the same manner, accompanied by Adriamycin 80 mg/M2 intravenously at the end of the infusion (2 patients), 6-thioguanine and cyclophosphainide in the manner described above (1 patient), and 6-thioguanine, cyclophosphamide and Adriamycin (1 patient). Twelve of the 14 patients w'ith AUL were treated initially with prednisone and vincristine in the same dosage as used for patients with ALL. If the blood blast cell count w%as the same or higher at the end of one week on this regimen, or if, in the absence at presentation of blast cells in the blood, a bone marrow-aspirate was not improved at the end of one week, therapy w-ith cytosine arabinoside and daunorubicin was substituted. The 2 other patients were treated w,ith the 24-h infusion regimen of cytosine arabinoside and daunorubicin without a prior trial of prednisone and vincristine. A complete remission w-as considered to have occurred when the patient became asymptomatic, had no abnormal physical signs, and when the blood count and marrow aspirate had returned to normal. Maintenance regimens for the patients with ALL varied, but all consisted of agents in standard use for ALL. Some of the regimens would be considered inadequate by current Fig. 4 and it can be seen that patients with ALL fare much better than the others. Predictive actuarial analysis of these data gives a median survival for the AUL patients of 3 months; the AML patients of 7 months and ALL patients of 45 months. These figures include patients who did not achieve remission.
The results of cytochemical staining with PAS and Sudan black stains are shown in Table II . The blast cells of only half the patients with ALL showed PAS positivity as defined by Hayhoe, Quaglino and Doll (1964) although it is probable that the disease is harder to control in adults than in children (Jacquillat et al., 1973) , the main problem nevertheless is not one of remission induction but of remission maintenance. Unnecessarily heavy chemotherapy at the time of remission induction may simply exacerbate that well recognized period of neutropenic susceptibility to infection that sometimes follows even therapy with prednisone and vincristine in this disease (Hughes and Smith, 1973) and lead to an unnecessary fatality. We do, however, give prophylactic therapy to the central nervous system once marrow remission has been obtained, and then use an intensive maintenance regimen. Not only is the complete remission rate much higher in ALL than in the other 2 diseases, but the predicted survival is longer.
Twenty-seven of 46 patients (59%) with AML achieved complete remission. Included in this group are patients with the variant forms-acute myelocytic, acute monomyelocytic and acute promyelocytic leukaemia-which Mathe et al. (1971) have shown to be associated with a poor prognosis. We have refrained from separating these variants off as no practical therapeutic advantage is gained by doing so. In acute myelogenous leukaemia the main problem is the relative ineffectiveness of the best agents available cytosine arabinoside in combination with daunorubicin, or 6-thioguanine, or 6-mercaptopurine.
Only 2 of 14 patients with acute undifferentiated leukaemia achieved complete remission, and the problem in this disease is the same as in AML but more serious-the ineffectiveness of drugs used 19 in attempting to induce remission. This group is probably comprised of the acute monoblastic and acute promyeloblastic leukaemias described by Mathe et It is not pretended that the proposed classification, whose only criteria are the presence of myeloid differentiation and the nuclear-cytoplasmic ratio, solves all the problems of the classification of adult acute leukaemia. However, it has the advantages of extreme simplicity, definite chemotherapeutic implications and prognostic value.
